KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) EBT (2016 - 2025)

Historic EBT for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q3 2025 value amounting to -$90.2 million.

  • Xenon Pharmaceuticals' EBT fell 4295.52% to -$90.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$314.7 million, marking a year-over-year decrease of 4716.79%. This contributed to the annual value of -$243.4 million for FY2024, which is 3324.03% down from last year.
  • Latest data reveals that Xenon Pharmaceuticals reported EBT of -$90.2 million as of Q3 2025, which was down 4295.52% from -$85.3 million recorded in Q2 2025.
  • In the past 5 years, Xenon Pharmaceuticals' EBT ranged from a high of -$15.6 million in Q3 2021 and a low of -$90.2 million during Q3 2025
  • Moreover, its 5-year median value for EBT was -$44.9 million (2023), whereas its average is -$45.8 million.
  • Per our database at Business Quant, Xenon Pharmaceuticals' EBT plummeted by 1033271.03% in 2021 and then tumbled by 1467.77% in 2024.
  • Over the past 5 years, Xenon Pharmaceuticals' EBT (Quarter) stood at -$25.1 million in 2021, then plummeted by 44.56% to -$36.3 million in 2022, then decreased by 23.97% to -$44.9 million in 2023, then tumbled by 65.8% to -$74.5 million in 2024, then fell by 21.06% to -$90.2 million in 2025.
  • Its EBT was -$90.2 million in Q3 2025, compared to -$85.3 million in Q2 2025 and -$64.6 million in Q1 2025.